Published Evidence

This article discusses the cost benefits that may be anticipated with the use of RECELL for surgical & traumatic full-thickness wounds.

The RECELL GO device aids in the preparation of a comparable skin cell suspension to the previous device with improved standardization and reduced variability in cell count.

In patients with nonthermal full-thickness wounds, treatment with RECELL plus widely meshed autograft significantly reduced donor skin requirements by 27% compared to less widely meshed autografting.

In porcine full-thickness wounds treated with 3:1 meshed autograft, the addition of RECELL significantly increased rate of re-epithelialization of interstices at early time points.

Use of RECELL for small burns (<20% TBSA) in U.S. centers was associated with an average 2.1 day reduction in length of stay, translating to a $22,268 cost savings per patient.

Use of RECELL for burns up to 50% TBSA in U.S. centers was associated with an average 3.3 day reduction in length of stay, translating to a $36,949 cost savings per patient.

Economic models demonstrate that hospital length of stay accounts for up to 70% of cost reductions, with estimated per-patient savings ranging from $31,000 to over $150,000, and projected annual savings of $5.3 to $6.8 million for a representative U.S. burn center treating 200 patients.

In patients with mixed-depth burns (inclusive of full-thickness), treatment with RECELL plus widely meshed autograft significantly reduced donor skin requirements by 32% compared to less widely meshed autografting.

In patients with deep partial-thickness burns, treatment with RECELL alone significantly reduced donor skin requirements by 97.5% compared to 2:1 meshed autografting. The RECELL donor site resulted in significantly less pain, faster healing, and improved patient satisfaction.

In patients with partial-thickness burns, treatment with RECELL alone resulted in decreased donor size and comparable healing outcomes compared to meshed autografting alone.

In porcine full-thickness wounds treated with 3:1 meshed autograft, the addition of RECELL resulted in faster and better quality of epithelialization at the cellular level.

In (mostly pediatric) patients with partial-thickness burns, treatment with PermeaDerm significantly reduced the odds of needing a dressing change compared to Mepilex Ag.

PermeaDerm performed as a viable option for temporizing full-thickness wounds, The authors concluded that PermeaDerm is an effective alternative to allograft, delivering similar clinical outcomes while offering advantages like simplified storage, reduced cost, easier application, and optimized management.

In pediatric patients with partial-thickness hand burns, the PermeaDerm glove resulted in successful healing with minimal scarring, preserved joint mobility, and minimal need for dressing changes.

PermeaDerm transferred oxygen significantly faster than Integra® Dermal Regeneration Template and NovoSorb™ Biodegradable Temporizing Matrix, suggesting its potential to enhance wound healing by improving oxygenation delivery.

In full-thickness porcine wounds, those treated with PermeaDerm healed more effectively and showed potential to reduce excessive scar formation compared to those not treated.

PermeaDerm supported cell growth and reduced scar-associated myofibroblast formation and inflammatory cytokines.

PermeaDerm demonstrated better control of inflammation, reduced scarring markers, and superior cell growth and migration compared to Biobrane®.

Cohealyx supported wound bed vascularization within 5-10 days, demonstrating its clinical potential as a dermal matrix option to support timely graft-readiness.

Cohealyx supported graft readiness of a full-thickness neck injury in 12 days, demonstrating its clinical potential to support definitive closure with excellent clinical performance and conformability in complex anatomical locations.

In full-thickness porcine wounds, Cohealyx supported rapid cellular infiltration and vascularized tissue formation, supporting autograft readiness at Day 7 and earlier definitive closure compared to Integra® Bilayer Wound Matrix and Kerecis®.